Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.81B | 4.10B | 3.43B | 3.65B | 3.56B |
| Total Other Revenue | 310.00M | 193.30M | 171.20M | 238.60M | 198.20M |
| Total Revenue | 5.12B | 4.29B | 3.61B | 3.88B | 3.75B |
| Cost of Revenue | 2.37B | 2.21B | 2.21B | 2.21B | 2.00B |
| Gross Profit | 2.75B | 2.08B | 1.39B | 1.67B | 1.76B |
| SG&A Expenses | 677.80M | 662.10M | 647.70M | 775.00M | 657.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 0.00 | -10.00M |
| Total Operating Expenses | 3.05B | 2.87B | 2.86B | 2.99B | 2.64B |
| Operating Income | 2.07B | 1.42B | 744.80M | 898.60M | 1.11B |
| Income Before Tax | 2.28B | 1.53B | 831.20M | 1.04B | 1.76B |
| Income Tax Expenses | 335.40M | 230.90M | 104.00M | 199.10M | 303.30M |
| Earnings from Continuing Operations | 1.95B | 1.30B | 727.20M | 844.60M | 1.46B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.95B | 1.30B | 727.20M | 844.60M | 1.46B |
| EBIT | 2.07B | 1.42B | 744.80M | 898.60M | 1.11B |
| EBITDA | 2.19B | 1.54B | 868.00M | 1.04B | 1.25B |
| EPS Basic | 19.16 | 12.62 | 6.99 | 8.21 | 14.09 |
| Normalized Basic EPS | 13.80 | 9.68 | 5.46 | 12.39 | 7.65 |
| EPS Diluted | 18.45 | 12.23 | 6.75 | 7.86 | 13.62 |
| Normalized Diluted EPS | 13.29 | 9.39 | 5.27 | 11.86 | 7.40 |
| Average Basic Shares Outstanding | 101.70M | 102.80M | 104.00M | 102.90M | 103.60M |
| Average Diluted Shares Outstanding | 105.60M | 106.00M | 107.70M | 107.50M | 107.20M |
| Dividend Per Share | 0.94 | 0.94 | 0.94 | 0.88 | 0.88 |
| Payout Ratio | 4.91% | 7.46% | 13.45% | 10.98% | 6.25% |